NEW YORK – UK-based Randox Laboratories said this week that its multiplex assay for 10 sexually transmitted infections has received CE marking.
The cartridge-based test is performed on the molecular point-of-care Vivalytic platform, which was codeveloped by German company Bosch. The system leverages Randox's Biochip Technology, a multiplex, PCR-based method. According to Randox, benefits of the Vivalytic system include the ability to detect multiple STIs, including co-infections, from one patient sample; a full molecular workflow; and small size.
Randox's test can be used to diagnose Chlamydia trachomatis; Neisseria gonorrhoeae; Trichomonas vaginalis; Mycoplasma genitalium; Treponema pallidum; herpes simplex virus 1; herpes simplex virus 2; Haemophilus ducreyl; Mycoplasm hominis; and Ureaplasma urealyticum. Â